Protalix BioTherapeutics, Inc. PLX
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +45.00%
- 1 year
- +9.21%
- Market cap
- 210.29M
- Revenue (ttm)
- 38.05M
- Profit margin
- -38.62%
- EPS (ttm)
- 0.23
- Shares out
- 73.63M
- P/E ratio
- 11.35
- Forward P/E
- 2.79
- YTD return
- +45.00%
- 1-year return
- +9.21%
- Volume
- 289.04K
- Avg volume
- 780.72K
- Open
- 2.57
- Previous close
- 2.56
- Day's range
- 2.52 – 2.61
- 52-week range
- 1.65 – 3.19
- Beta
- 0.67
- Price target
- 14.00 (+436.4%)
2Y +1.33 (+103.91%)
Key statistics
- Enterprise value
- 84.82M
- PEG ratio
- 0.00
- Price / sales
- 3.35
- Price / book
- 3.76
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -61.60%
- Free cash flow
- 1.32M
- Total cash
- 45.03M
- Total debt
- 26.15M
- Return on equity
- -43.48%
- Short % of float
- 4.41%
- 50-day average
- 1.43
- 200-day average
- 1.21
Analyst view
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.06 | 0.03 | -0.03 | -50.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.02 | -0.03 | -0.05 | -250.00% |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.06 | — | — |
| Mar 14, 2024 | Dec 1, 2023 | -0.03 | -0.07 | -0.04 | -133.33% |
| Nov 6, 2023 | Sep 1, 2023 | -0.07 | -0.04 | +0.03 | +42.86% |
| Aug 7, 2023 | Jun 1, 2023 | -0.04 | 0.21 | +0.25 | +625.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- protalix.com
News
Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026 
Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 
HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target 
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences 
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript 
Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate 
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results 
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
Your note
Sign in to keep a note on PLX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASHAN DROR | Chief Executive Officer | Stock Award(Grant) | Mar 31, 2024 | 0 |
| HAYON YAEL | Officer | Stock Award(Grant) | Aug 14, 2023 | 0 |
| NAOS YARON | Officer | Stock Award(Grant) | Aug 14, 2023 | 0 |
| RUBIN EYAL | Chief Financial Officer | Stock Award(Grant) | Sep 22, 2024 | 0 |
| SCHWARTZ AHARON | Director | Purchase | Jan 2, 2023 | 174,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 1.30% | 955,900 | 1.65M | Sep 29, 2024 |
| Gsa Capital Partners Llp | 0.59% | 435,213 | 752.92K | Sep 29, 2024 |
| Millennium Management Llc | 0.51% | 373,757 | 646.60K | Sep 29, 2024 |
| Stratos Wealth Partners, Ltd. | 0.37% | 270,000 | 467.10K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.25% | 183,790 | 317.96K | Sep 29, 2024 |
| Blackrock Inc. | 0.24% | 178,784 | 309.30K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.24% | 180,000 | 311.40K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.22% | 162,696 | 281.46K | Oct 30, 2024 |
| EQ Advisors Trust-1290 VT Micro Cap Port | 0.02% | 14,966 | 25.89K | Sep 29, 2024 |
| Northern Small Cap Core Fund | 0.00% | 503 | 870 | Sep 29, 2024 |
| John Hancock Var Ins Tr-Total Stock Market Index Tr | 0.00% | 640 | 1.11K | Sep 29, 2024 |